Pacific Edge reviews US pricing for new Cxbladder test, trading halted

Pacific Edge reviews US pricing for new Cxbladder test, trading halted
Pacific Edge says Cxbladder Triage Plus delivers “significant performance improvements” compared to its existing tests. (Image: Pacific Edge)
Rebecca Howard
Pacific Edge has been placed on a trade halt while it reviews draft gapfill or reimbursement rates for its new Cxbladder Triage Plus test from the US Centres for Medicare and Medicaid Services.“[It said it's] reviewing the prices and the associated documentation and needs time to assess the implications of them, consult with its advisers and industry partners, and prepare an announcement that provides context to investors.”Gapfill prices are proposed reimbursement rates for new or unpriced clinical diagnostic laboratory tests.Th...

More Markets

Nvidia slump drags Wall Street and NZ sharemarket lower
Markets Market Close

Nvidia slump drags Wall Street and NZ sharemarket lower

The S&P/NZX 50 Index closed 20 points or 0.15% down at 13,419.40.

Jamie Gray 21 Nov 2025
RBNZ reopens Wellington office after asbestos mayhem
Finance

RBNZ reopens Wellington office after asbestos mayhem

Bank tight-lipped on how many staff are home-working as asbestos-hit office reopens. 

Andy Macdonald 21 Nov 2025
Oceania Healthcare extends dividend freeze
Markets

Oceania Healthcare extends dividend freeze

The retirement village operator hasn't paid a dividend since June 2023.

John Anthony 21 Nov 2025